Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.
STERIS plc received a Form 144 notice for a proposed sale of 15,000 Ordinary shares. The filing lists an aggregate market value of $3,977,050 and an approximate sale date of 11/11/2025. The designated broker is Charles Schwab & Co., Inc., and the shares are to be sold on the NYSE.
The shares were acquired on 11/11/2025 via an employee stock option exercise with a broker payment for cashless exercise. This notice reflects an intended disposition by a holder under Rule 144.
STERIS plc reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $1,460.3 million from $1,328.9 million as Healthcare delivered $1,033.8 million, Applied Sterilization Technologies $281.5 million, and Life Sciences $145.0 million. Operating income increased to $265.8 million from $219.7 million, with net income attributable to shareholders of $191.9 million (diluted EPS $1.94) versus $150.0 million ($1.51) a year ago. The effective tax rate was 23.9%.
Through six months, operating cash flow was $707.8 million, funding capital spending of $180.1 million and supporting cash balances of $319.2 million. Total debt declined to $1,897.3 million from $2,043.7 million. The company repurchased 0.4 million shares for $100.0 million and paid dividends of $1.20 per share year-to-date. Remaining performance obligations were $1,926.4 million, with approximately 53% expected to be recognized within one year.
STERIS plc furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025, which is its fiscal 2026 second quarter. The press release is attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished to the SEC, not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference into Securities Act filings.
Massachusetts Financial Services Company filed an amended Schedule 13G reporting its beneficial ownership in STERIS plc (STE).
MFS reported beneficial ownership of 4,846,124 shares of STERIS common stock, representing 4.9% of the class as of the reported event date. The firm disclosed sole voting power over 4,674,537 shares and sole dispositive power over 4,846,124 shares, with no shared voting or shared dispositive power.
The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of STERIS.
Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on 10/06/2025 at a price of $241.82 per share, leaving beneficial ownership of 51,096 shares. The filing indicates 33,054 of those shares are restricted with scheduled lapses: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), and 06/05/2028 (5,937). The form is filed individually and indicates the transaction was reported under a Rule 10b5-1 plan.
STERIS plc filed a Form 144 reporting a proposed sale of 159 ordinary shares through Charles Schwab & Co., Inc. on 10/06/2025 with an aggregate market value of $38,449. The securities were acquired on 10/01/2025 by lapse of restricted stock granted as equity compensation. The filing lists 98,490,606 shares outstanding, so the 159 shares represent an immaterial fraction of the company's outstanding stock. No other sales in the past three months are reported and the filer affirms they are not aware of undisclosed material adverse information.
John Adam Zangerle, Senior Vice President, General Counsel and Secretary of STERIS plc (STE), reported that 202 restricted ordinary shares awarded on October 1, 2021 vested on October 1, 2025. Of those vested shares, 91 were withheld to satisfy tax withholding obligations, recorded as a disposition. After the transaction, Mr. Zangerle beneficially owns 33,669 ordinary shares. The filing notes 8,511 ordinary shares remain restricted with staggered lapse dates between June 1, 2026 and June 5, 2028. The Form 4 was signed by an authorized representative on October 3, 2025.
STERIS plc (STE) reported insider activity by its V.P. & Corporate Treasurer. On 10/01/2025, 26 ordinary shares were withheld (Code F) to cover taxes upon vesting of 86 restricted shares originally granted on 10/01/2021. Following the transaction, the reporting person beneficially owns 7,195 shares.
As of 10/01/2025, 1,475 of these shares are restricted, with scheduled lapses of restrictions as follows: 241 on 06/01/2026; 141 on 06/02/2026; 217 on 06/03/2026; 221 on 06/04/2026; 217 on 06/03/2027; 221 on 06/04/2027; and 217 on 06/05/2028.
STERIS plc (STE) reporting person Cary L. Majors, identified as SVP and President, Healthcare, reported transactions dated 10/01/2025. 692 ordinary shares vested that day from an award granted on 10/01/2021; 303 of those shares were withheld to satisfy required taxes, with a reported price of $0 for the withholding entry. After the transaction, the report shows 13,427 ordinary shares beneficially owned (direct) and 67 share equivalents held in the STERIS Corporation 401(k) Plan (indirect) as of 10/02/2025. The filing notes 10,138 ordinary shares remain restricted with scheduled lapses between 06/01/2026 and 06/05/2028. The form is signed by an authorized representative on 10/03/2025.